SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use molecular glues to attack protein targets previously believed to be “undruggable”.
Science & Innovation
Maximizing molecular glue discovery success
Pipeline
SEED’s pipeline is focused on targeting key undruggable proteins across human disease.
Indication
Target Selection
E3 Ligase ID
Molecular Glue HTS
Lead ID
IND Candidate
IND Filing
Phase 1
Milestones
Indication:
Oncology
RBM39:
Apr 2025: AACR Presentation
Mid 2025: IND Cleared
1Q 2026: First Human Dose
Mid 2025: IND Cleared
1Q 2026: First Human Dose
KRAS-G12D:
Apr 2025: PROTAC Combo AACR Presentation
Indication:
Neurodegeneration
Tau:
2H 2025: In Vivo Activity
2H 2026 IND Candidate Selection
2H 2026 IND Candidate Selection
SEED owns global IP on all programs except for three partnered programs (labeled with *).
Science & Innovation
Target: RNA-binding motif protein 39 (RBM39) involved in RNA splicing and gene transcription. RBM39 overexpression is linked to cancer cell survival and resistance to therapy in multiple cancer types.
Indications: : RBM39 driven tumors including Ewing sarcoma, bile duct cancer, KRAS mutation positive colorectal cancer, testicular cancer, breast cancer, ovarian cancer, endometrial cancer, hepatocellular carcinoma, and neuroblastoma
Breakthrough Potential:
- In preclinical studies, ST-01156 causes total tumor regression in models of KRAS mutation positive colon cancer, Ewing sarcoma, and neuroblastoma without weight loss.
- ST-01156 showed potent anti-cancer activity against several patient-derived models, including carcinoma of the liver, biliary duct, testicular cancer and endometrial cancer.
- In Ewing sarcoma models, ST-01156 degrades RBM39 to target EWS-FLI1 fusion protein, the oncogenic driver in 90% of cases of Ewing sarcoma. ST-01156 has been granted Rare Pediatric Disease and Orphan Drug designation by the U.S. Food and Drug Administration (FDA).
Clinical Status: IND cleared August 2025; advancing to patient dosing at top U.S. cancer institutions
As described in Nature Reviews Drug Discovery (2024):
“Armed with a better understanding of RBM39 biology, SEED is set to advance an optimized RBM39 degrader into the clinic next year.”
Science & Innovation
Target: Tau, a neuronal protein that can aggregate to drive synapse and neuronal loss in several neurodegenerative conditions.
Indications: Alzheimer’s disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, and Pick’s disease.
Breakthrough Potential:
- Newly discovered lead chemical series glues Tau to a preferred RITE3™ selected novel E3 ligase for targeted protein degradation.
- Degradation of Tau achieved in human neuronal cells, utilizing a favored tau protein domain
Preclinical Status: Advancing towards in vivo activity with lead series; testing in mouse beginning 2H 2025
Science & Innovation
Target: Kristen rat sarcoma virus (KRAS) G12D mutant that drives uncontrolled cell growth and survival in multiple cancers by constitutively activating downstream signaling pathways such as MAPK and PI3K.
Indications: Pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, non-small cell lung cancer, and other KRAS/KRAS-G12D–driven solid tumors.
Breakthrough Potential:
- Breakthrough PROTAC combination discovered to achieve dramatic KRAS-G12D degradation in PDAC cells not achievable with monotherapy PROTACs.
- Proprietary molecular glue strategy initiated, targeting KRAS mutant cancer; projected to be SEED’s next IND in 4Q2027/1Q2028
Preclinical Status: PROTAC combination strategy advancing towards in vivo validation in 1H 2026; Molecular glue strategy targeting KRAS mutant cancers currently utilizing structure-based drug design and MedChem screening to advance to IND candidate selection in 2H 2026.